|Bid||30.65 x 1400|
|Ask||30.67 x 900|
|Day's Range||30.26 - 30.72|
|52 Week Range||17.04 - 31.93|
|Beta (5Y Monthly)||0.34|
|PE Ratio (TTM)||21.64|
|Earnings Date||Aug 04, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Feb 01, 2019|
|1y Target Est||30.00|
Subscribe to Yahoo Finance Plus to view Fair Value for VIVO
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new sample-specific master mixes, Lyo-Ready™ Direct DNA qPCR Stool Mix, and Lyo-Ready™ Direct RNA/DNA qPCR Stool Mix. These innovative master mixes improve the molecular detection of DNA and RNA from crude fecal specimens while allowing room temperature stabilization of diagnostic assays.
Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Most readers would already be aware that Meridian Bioscience's (NASDAQ:VIVO) stock increased significantly by 10% over...